Cerenome (PSTV) Cash from Financing Activities (2010 - 2026)
Plus Therapeutics (PSTV) posted quarterly Cash from Financing Activities of $9.0 million for Q1 2026, down 27.17% year-over-year from $12.4 million in Q1 2025, and up 222.33% quarter-over-quarter from $2.8 million in Q4 2025.
Cerenome (PSTV) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Cash from Financing Activities for 17 consecutive years, with $9.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 27.17% year-over-year to $9.0 million; the TTM figure through Mar 2026 stood at $26.9 million (up 39.1% YoY), while the FY2025 annual figure was $30.3 million, up 389.91% from the prior year.
- Cash from Financing Activities climbed to $9.0 million in Q1 2026 per PSTV's latest filing, from $2.8 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $12.4 million in Q1 2025 and bottomed at -$776000.0 in Q1 2024.
- Historically, Cash from Financing Activities has averaged $4.2 million across 5 years, with a median of $2.8 million in 2025.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities tumbled 634.34% — and 2025, when it surged 1698.58%.
- Plus Therapeutics' Cash from Financing Activities stood at $99000.0 in 2022, then sank by 634.34% to -$529000.0 in 2023, then soared by 1416.26% to $7.0 million in 2024, then tumbled by 59.74% to $2.8 million in 2025, then jumped by 222.33% to $9.0 million in 2026.
- Business Quant data shows PSTV's Cash from Financing Activities at $9.0 million in Q1 2026, $2.8 million in Q4 2025, and $12.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | 1.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.04 Mn |
| Mar 31, 2026 | 9.04 Mn |
| Dec 31, 2025 | 2.80 Mn |
| Dec 31, 2025 | 2.80 Mn |
| Sep 30, 2025 | 12.31 Mn |
| Sep 30, 2025 | 12.31 Mn |
| Jun 30, 2025 | 2.80 Mn |
| Jun 30, 2025 | 2.80 Mn |
| Mar 31, 2025 | 12.41 Mn |
| Mar 31, 2025 | 12.41 Mn |
| Jun 30, 2024 | 6.96 Mn |
| Jun 30, 2024 | 6.96 Mn |
| Mar 31, 2024 | -776,000.00 |
| Mar 31, 2024 | -776,000.00 |
| Dec 31, 2023 | -529,000.00 |
| Dec 31, 2023 | -529,000.00 |
| Sep 30, 2023 | 2.52 Mn |
| Sep 30, 2023 | 2.52 Mn |
| Jun 30, 2023 | 961,000.00 |
| Jun 30, 2023 | 961,000.00 |